Novo Nordisk Investing $73M in Clayton, North Carolina, Facility
10/04/2010
"The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment," said Jerzy Gruhn, president of Novo Nordisk Inc. "Insulin delivery devices give people with diabetes a convenient way to manage their health and engage in a productive lifestyle. As patients in the U.S. continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand."
The facility produces Novo Nordisk products including the Levemir FlexPen. The expansion will add two final assembly lines, two packing lines, along with refurbishing the building.
Cost and productivity factors, including state and local incentives, helped Novo Nordisk choose Clayton. The company has been approved for Job Development Investment Grant funds, as well as a $400,000 One North Carolina Fund grant.
Project Announcements
AESC Expands Florence, South Carolina, Operations
03/28/2024
Alticor Expands Ada Township, Michigan, Operations
03/27/2024
Eastman Plans Longview, Texas, Production Operations
03/27/2024
DHL Supply Chain-Vantage Data Centers NV11 Plan Nevada Operations
03/26/2024
Big Jet Expands Pittsburgh, Pennsylvania, Operations
03/26/2024
Landmark Ceramics UST Expands Mt. Pleasant, Tennessee, Operations
03/25/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The Logistics Analysis That Drives Industrial Site Selection
Q4 2023
-
Manufacturing Momentum Is Building
Q1 2024
-
Technology’s Influence on Workforce Development
Workforce Q4 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023